Diakonos Oncology Expands Phase 2 Glioblastoma Trial Across 14 U.S. Sites

According to a recent LinkedIn post from Diakonos Oncology Corp, the company’s Phase 2 glioblastoma trial is currently active at 14 sites across the United States, including both leading academic centers and community hospitals. The post indicates that this site mix is intended to improve geographic accessibility and broaden patient participation in the study.

The company’s LinkedIn post highlights an immunotherapy platform that uses each patient’s own tumor biology to inform immune activation. The post suggests this approach has produced promising efficacy signals and what is described as an excellent safety profile so far, which, if sustained in larger datasets, could enhance the company’s clinical value proposition.

From an investor perspective, the advancement of a Phase 2 trial in glioblastoma, a high‑unmet‑need oncology indication, may position Diakonos Oncology within a competitive but strategically important niche. Broader site coverage across the U.S. could support faster enrollment and more generalizable data, factors that are often important in attracting partners or future funding.

If the reported efficacy and safety trends are corroborated in formal trial readouts, this could strengthen the company’s case for subsequent‑stage studies or potential collaboration with larger biopharmaceutical firms. However, the post does not provide quantitative data, timelines, or regulatory milestones, so investors may need to monitor future disclosures for more concrete indicators of clinical and commercial potential.